, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
, Manolio TA, Kuller LH. Incidence of and risk factors for atrial fibrillation in older adults.
. Management of atrial fibrillation: therapeutic options and clinical decisions.
Am J Cardiol.
Arch Intern Med.
, Kuck KH, Lilienthal J. Rhythm versus rate control in atrial fibrillation—Pharmacological intervention in atrial fibrillation (PIAF): a randomised trial.
, Anderson JL, Gilbert EM. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study.
Am Heart J.
, Margiotti R, Fogel R, Evans JJ, Freedberg N, Shaar C. Atrial fibrillation with and without heart disease: clinical characteristics and proarrhythmia risk (Abstr).
, Marek M, Coumel P. on behalf of the French Cardiologists. Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA study.
, Menozzi C, Gianfranchi L. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. A randomized controlled study.
, Chen A, Tai C. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular modification in patients with medically refractory atrial fibrillation.
J Am Coll Cardiol.
, Crijns HJGM, van den Berg MP. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study.
Br Heart J.
Am J Cardiol.
This content is only available as a PDF.
The European Society of Cardiology